PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2022 ENDED MARCH 31, 2022
PetVivo Holdings (NASDAQ: PETV, PETVW) will report its financial results for the year ending March 31, 2022, on June 29, 2022, after market close. A conference call will take place at 4:00 p.m. CT to discuss these results. Investors can access the live webcast and related materials via the company's Investor Relations website. PetVivo is focused on developing medical devices and therapeutics for companion animals, emphasizing a strategy that leverages human therapies. The company has a pipeline of seventeen products and a portfolio of twenty-one patents.
- Focus on innovative medical devices for companion animals enhances potential market growth.
- Strategic aim to leverage human therapies could lead to faster market entry and revenue generation.
- Existing product SPRYNG™ for managing osteoarthritis has been commercially available since September 2021.
- None.
MINNEAPOLIS, MN, US, June 21, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for companion animals, will report financial results for the year ending March 31, 2022, on Wednesday, June 29, 2022 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day.
Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo’s Investor Relations website at:
https://audience.mysequire.com/webinar-view?webinar_id=4247f378-9329-46f0-adcf-44720e7f5ae6
A replay of the webcast will be available through the same link following the conference call. Participants can also access the call using the dial-in details below.
Date: Wednesday, June 29, 2022
Time: 4:00 p.m. CT (5:00 p.m. ET)
Dial-in number: +1 (346) 248-7799
Conference ID: 97245185036
Passcode: 740720
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV and PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of dogs and horses in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™, a veterinarian-administered, intraarticular injection for the management of osteoarthritis in dogs and horses, was made available for commercial sale in September, 2021.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
FAQ
When will PetVivo Holdings report its financial results for 2022?
What is the time for PetVivo Holdings' conference call?
How can I access the PetVivo Holdings conference call?
What product has PetVivo launched for companion animals?
